Sera Prognostics Inc (SERA) is a Healthcare · Medical Devices company listed on NASDAQ. Price $2.13 (+2.90%), Market cap $0.07B, 52-week low–high $1.49 ~ $4.09.
Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation. It is also involved in the development of a pipeline of novel blood-based biomarker tests and predictive analytic products and services for pregnancy related conditions, such as time-to-birth, predictive analytics product, pregnancy risk prediction panel, preeclampsia, and fetal growth restriction. The company was incorporated in 2008 and is headquartere
Financial statements, price targets, institutional (13F) holdings and related news for Sera Prognostics Inc are updated in real time on BlackAll Trade.
Sera Prognostics Inc trades at $2.13 (+2.90%). Real-time quotes and charts are available on BlackAll Trade.
Sera Prognostics Inc has a market cap of about $0.07B.
Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States. The company d